Evaluation of the Cellsway Microfluidic CTC Enrichment and Identification Platform for CTC Detection in Metastatic NSCLC
Authors:
- Ebru ÖzgürEÖEbru Özgür
- Ayça ÇırçırAÇAyça Çırçır
- Begüm Şen DoğanBegüm Şen Doğan
- Şebnem ŞahinŞŞŞebnem Şahin
- Gizem KarayalçınGKGizem Karayalçın
- Mehmet Alper DemirMDMehmet Alper Demir
- Başak ErkekBEBaşak Erkek
- Enes DemirtaşEDEnes Demirtaş
- Özge ZorluÖZÖzge Zorlu
- Furkan CeylanFCFurkan Ceylan
- Haluk KülahHKHaluk Külah
- Nuri KaradurmuşNKNuri Karadurmuş
Open Access
- 2 January 2026
- journal article
- research article
- Published by MDPI AG in Biosensors
- Vol. 16 (1) , 34
Abstract
Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small-cell lung cancer (NSCLC) accounting for the majority of cases. Standard tissue biopsies are invasive and unsuitable for repeated monitoring. Liquid biopsy technologies, particularly circulating tumor cell (CTC) analysis, offer a minimally invasive alternative for real-time disease tracking. To address the need for efficient and reproducible CTC isolation, we developed the Cellsway microfluidic CTC enrichment and identification platform, which employs inertial hydrodynamics in a spiral-shaped microfluidic channel comprising hydrofoil-shaped pillars to enable high-throughput, label-free enrichment of CTCs while preserving cell integrity, followed by an optimized CTC identification assay. Analytical performance assessed through spiking experiments using NSCLC cell lines demonstrated recovery rates of 91.9% for H1975 cells and 78.3% for A549 cells. Clinical validation was performed on blood samples from 51 stage IV NSCLC patients. A 7.5 mL volume of peripheral blood was processed with the SwayBox platform, and enriched CTCs were identified through an optimized multiplex immunofluorescence protocol. CTCs were detected in 47% of NSCLC patients, with counts ranging from 0 to 72 cells per 7.5 mL of blood. At a cutoff of 1 CTC per 7.5 mL, the assay achieved a specificity of 95%. Patient-derived CTCs exhibited smaller mean diameters compared to cultured NSCLC cell lines, yet were effectively enriched through hydro-dynamic tuning. These findings demonstrate that the Cellsway platform enables efficient and re-producible CTC isolation with high specificity, supporting its potential utility for clinical monitoring and precision oncology in NSCLC.Keywords
Funding Information
- Cellsway Limited
This publication has 77 references indexed in Scilit:
- Distinct CTC Specific RNA Profile Enables NSCLC Early Detection and Dynamic Monitoring of Advanced NSCLCAdvanced Science, 2025
- Opportunities and challenges of using circulating tumor DNA to predict lung cancer immunotherapy efficacyJournal of Cancer Research and Clinical Oncology, 2024
- Measurable morphological features of single circulating tumor cells in selected solid tumors—A pilot studyCytometry Part A, 2024
- A comparative study of circulating tumor cell isolation and enumeration technologies in lung cancerMolecular Oncology, 2024
- Comparative evaluation of PD‐L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non‐small cell lung cancer patientsMolecular Oncology, 2023
- Powering single-cell genomics to unravel circulating tumour cell subpopulations in non-small cell lung cancer patientsJournal of Cancer Research and Clinical Oncology, 2022
- Defining the dimensions of circulating tumor cells in a large series of breast, prostate, colon, and bladder cancer patientsMolecular Oncology, 2020
- VTX‐1 Liquid Biopsy System for Fully‐Automated and Label‐Free Isolation of Circulating Tumor Cells with Automated Enumeration by BioView PlatformCytometry Part A, 2018
- The Parsortix™ Cell Separation System—A versatile liquid biopsy platformCytometry Part A, 2018
- Detection of circulating tumor cells as a prognostic factor in patients undergoing radical surgery for non‐small‐cell lung carcinoma: comparison of the efficacy of the CellSearch Assay™ and the isolation by size of epithelial tumor cell methodInternational Journal of Cancer, 2010